Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
AVIR 
Atea Pharmaceuticals Inc (AVIR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: AVIR (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $7.5
1 Year Target Price $7.5
| 1 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 13.22% | Avg. Invested days 25 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 275.37M USD | Price to earnings Ratio - | 1Y Target Price 7.5 |
Price to earnings Ratio - | 1Y Target Price 7.5 | ||
Volume (30-day avg) 3 | Beta 0.25 | 52 Weeks Range 2.46 - 4.14 | Updated Date 08/29/2025 |
52 Weeks Range 2.46 - 4.14 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.62 |
Earnings Date
Report Date 2025-08-07 | When - | Estimate -0.41 | Actual -0.44 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -20.16% | Return on Equity (TTM) -32.38% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -103096292 | Price to Sales(TTM) 1.9 |
Enterprise Value -103096292 | Price to Sales(TTM) 1.9 | ||
Enterprise Value to Revenue 58.97 | Enterprise Value to EBITDA -260.47 | Shares Outstanding 79357600 | Shares Floating 60009388 |
Shares Outstanding 79357600 | Shares Floating 60009388 | ||
Percent Insiders 12.72 | Percent Institutions 71.89 |
Upturn AI SWOT
Atea Pharmaceuticals Inc
Company Overview
History and Background
Atea Pharmaceuticals, Inc. (AVIR) is a biopharmaceutical company founded in 2014. It focuses on discovering, developing, and commercializing oral therapies for serious viral diseases. The company went public in October 2020.
Core Business Areas
- Antiviral Therapies: Atea develops orally administered therapies to address unmet needs in the treatment of viral infections, focusing on diseases such as COVID-19 and hepatitis C.
Leadership and Structure
The leadership team includes Jean-Pierre Sommadossi, PhD, the founder and CEO. The organizational structure is typical of a biotechnology company, with research, development, clinical, and commercial functions.
Top Products and Market Share
Key Offerings
- Bemnifosbuvir (AT-527): An oral antiviral drug for the treatment of COVID-19. Development was discontinued due to unfavorable data. Competitors include Pfizer (PAXLOVID), Merck (LAGEVRIO), and Gilead Sciences (VEKLURY).
Market Dynamics
Industry Overview
The antiviral drug market is large and growing, driven by the emergence of new viral threats and the need for more effective treatments for existing viral infections. The COVID-19 pandemic significantly increased demand for antiviral therapies.
Positioning
Atea aimed to develop best-in-class oral antivirals. However, bemnifosbuvir failing put Atea at a disadvantage and the company is trying to find new opportunities
Total Addressable Market (TAM)
The global antiviral drugs market is estimated to be in the tens of billions of dollars. Atea's success depends on its pipeline. Current market positioning has Atea missing out on a large portion of the TAM due to its failed trials.
Upturn SWOT Analysis
Strengths
- Experienced Leadership
- Focus on oral antiviral therapies
Weaknesses
- Failed Clinical Trials (Bemnifosbuvir)
- Limited product pipeline
- Reliance on future clinical trial results
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into other viral disease areas
Threats
- Competition from established pharmaceutical companies
- Clinical trial failures
- Regulatory hurdles
Competitors and Market Share
Key Competitors
- PFE
- MRK
- GILD
Competitive Landscape
Atea faces intense competition from established pharmaceutical giants with greater resources and broader pipelines. The company's success hinges on its ability to innovate and differentiate its products.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been limited due to lack of product on the market.
Future Projections: Future growth depends on the company's ability to successfully develop and commercialize new antiviral therapies. Analyst estimates may be highly variable, reflecting the inherent risks in the biotech industry.
Recent Initiatives: Focusing on early stage therapies and licensing agreements.
Summary
Atea Pharmaceuticals is a high-risk, high-reward biotechnology company that is attempting a comeback with a new drug. The company's future depends on the successful development and commercialization of its remaining pipeline assets. Failure to achieve positive clinical trial results could have a significant negative impact on the company's stock price. Atea's focus on oral antiviral therapies is a positive sign, but they are still struggling from the Bemnifosbuvir fail.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings (SEC)
- Market Research Reports
- Analyst Estimates
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual risk tolerance and thorough due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Atea Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Boston, MA, United States | ||
IPO Launch date 2020-10-30 | Founder, Chairman, CEO & President Dr. Jean-Pierre Sommadossi Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 56 | Website https://ateapharma.com |
Full time employees 56 | Website https://ateapharma.com | ||
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.